Cardiovascular effects of tibolone: A selective tissue estrogenic activity regulator
Traditionally, it was accepted that long-term hormone replacement therapy (HRT) has a cardiovascular beneficial effect in postmenopausal women with and without coronary artery disease (CAD). However, randomized trials in postmenopausal women have not shown any benefit in either primary or secondary...
| Publicado: |
2007
|
|---|---|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_08975957_v25_n2_p132_Campisi http://hdl.handle.net/20.500.12110/paper_08975957_v25_n2_p132_Campisi |
| Aporte de: |
| id |
paper:paper_08975957_v25_n2_p132_Campisi |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_08975957_v25_n2_p132_Campisi2023-06-08T15:49:20Z Cardiovascular effects of tibolone: A selective tissue estrogenic activity regulator Atherosclerosis Endothelial function Heart disease Menopause Tibolone 3 alpha hydroxytibolone 3 beta hydroxytibolone C reactive protein conjugated estrogen plus medroxyprogesterone acetate drug metabolite endothelial leukocyte adhesion molecule 1 estradiol plus norethisterone acetate estrogen estrogen receptor alpha estrogen receptor beta high density lipoprotein cholesterol homocysteine intercellular adhesion molecule 1 nitrate nitric oxide nitrite progesterone tibolone unclassified drug vascular cell adhesion molecule 1 abdominal pain antiinflammatory activity artery intima proliferation atherosclerosis blood clotting cardiovascular disease cardiovascular effect cardiovascular system cholesterol blood level chronotropism clinical trial coronary artery disease coronary risk drug blood level drug mechanism drug metabolism estrogen activity heart arrhythmia heart muscle ischemia heart protection hormone substitution human inflammation kidney function leukorrhea liver function mastalgia nonhuman postmenopause primary prevention priority journal review secondary prevention side effect tissue specificity vagina bleeding vascular endothelium vasodilatation venous thromboembolism weight gain Animals Atherosclerosis Blood Coagulation Cardiovascular System Coronary Disease Estrogen Receptor Modulators Female Humans Menopause Middle Aged Norpregnenes Tunica Intima Traditionally, it was accepted that long-term hormone replacement therapy (HRT) has a cardiovascular beneficial effect in postmenopausal women with and without coronary artery disease (CAD). However, randomized trials in postmenopausal women have not shown any benefit in either primary or secondary prevention of cardiovascular events. Therefore, these findings have raised the question of whether traditional HRT (i.e., estrogen and progesterone) has a cardioprotective effect in women at risk for or with established CAD. Concerns about the use of conventional HRT have led to a search for alternatives. Tibolone is a synthetic compound with estrogenic, androgenic, and progestogenic properties that relieves climacteric symptoms and prevents postmenopausal bone loss. Tibolone possesses a tissue-selective mechanism of action that differs from that of estrogen and/or progestogen. Unlike these compounds, tibolone's metabolites play a central role in its mode of action. Tibolone is widely used for HRT. However, its clinical impact on cardiovascular disease is still under study. The current review focuses on the effects of tibolone on the cardiovascular system and discusses clinical investigations with this compound in postmenopausal women. © 2007 The Authors. 2007 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_08975957_v25_n2_p132_Campisi http://hdl.handle.net/20.500.12110/paper_08975957_v25_n2_p132_Campisi |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Atherosclerosis Endothelial function Heart disease Menopause Tibolone 3 alpha hydroxytibolone 3 beta hydroxytibolone C reactive protein conjugated estrogen plus medroxyprogesterone acetate drug metabolite endothelial leukocyte adhesion molecule 1 estradiol plus norethisterone acetate estrogen estrogen receptor alpha estrogen receptor beta high density lipoprotein cholesterol homocysteine intercellular adhesion molecule 1 nitrate nitric oxide nitrite progesterone tibolone unclassified drug vascular cell adhesion molecule 1 abdominal pain antiinflammatory activity artery intima proliferation atherosclerosis blood clotting cardiovascular disease cardiovascular effect cardiovascular system cholesterol blood level chronotropism clinical trial coronary artery disease coronary risk drug blood level drug mechanism drug metabolism estrogen activity heart arrhythmia heart muscle ischemia heart protection hormone substitution human inflammation kidney function leukorrhea liver function mastalgia nonhuman postmenopause primary prevention priority journal review secondary prevention side effect tissue specificity vagina bleeding vascular endothelium vasodilatation venous thromboembolism weight gain Animals Atherosclerosis Blood Coagulation Cardiovascular System Coronary Disease Estrogen Receptor Modulators Female Humans Menopause Middle Aged Norpregnenes Tunica Intima |
| spellingShingle |
Atherosclerosis Endothelial function Heart disease Menopause Tibolone 3 alpha hydroxytibolone 3 beta hydroxytibolone C reactive protein conjugated estrogen plus medroxyprogesterone acetate drug metabolite endothelial leukocyte adhesion molecule 1 estradiol plus norethisterone acetate estrogen estrogen receptor alpha estrogen receptor beta high density lipoprotein cholesterol homocysteine intercellular adhesion molecule 1 nitrate nitric oxide nitrite progesterone tibolone unclassified drug vascular cell adhesion molecule 1 abdominal pain antiinflammatory activity artery intima proliferation atherosclerosis blood clotting cardiovascular disease cardiovascular effect cardiovascular system cholesterol blood level chronotropism clinical trial coronary artery disease coronary risk drug blood level drug mechanism drug metabolism estrogen activity heart arrhythmia heart muscle ischemia heart protection hormone substitution human inflammation kidney function leukorrhea liver function mastalgia nonhuman postmenopause primary prevention priority journal review secondary prevention side effect tissue specificity vagina bleeding vascular endothelium vasodilatation venous thromboembolism weight gain Animals Atherosclerosis Blood Coagulation Cardiovascular System Coronary Disease Estrogen Receptor Modulators Female Humans Menopause Middle Aged Norpregnenes Tunica Intima Cardiovascular effects of tibolone: A selective tissue estrogenic activity regulator |
| topic_facet |
Atherosclerosis Endothelial function Heart disease Menopause Tibolone 3 alpha hydroxytibolone 3 beta hydroxytibolone C reactive protein conjugated estrogen plus medroxyprogesterone acetate drug metabolite endothelial leukocyte adhesion molecule 1 estradiol plus norethisterone acetate estrogen estrogen receptor alpha estrogen receptor beta high density lipoprotein cholesterol homocysteine intercellular adhesion molecule 1 nitrate nitric oxide nitrite progesterone tibolone unclassified drug vascular cell adhesion molecule 1 abdominal pain antiinflammatory activity artery intima proliferation atherosclerosis blood clotting cardiovascular disease cardiovascular effect cardiovascular system cholesterol blood level chronotropism clinical trial coronary artery disease coronary risk drug blood level drug mechanism drug metabolism estrogen activity heart arrhythmia heart muscle ischemia heart protection hormone substitution human inflammation kidney function leukorrhea liver function mastalgia nonhuman postmenopause primary prevention priority journal review secondary prevention side effect tissue specificity vagina bleeding vascular endothelium vasodilatation venous thromboembolism weight gain Animals Atherosclerosis Blood Coagulation Cardiovascular System Coronary Disease Estrogen Receptor Modulators Female Humans Menopause Middle Aged Norpregnenes Tunica Intima |
| description |
Traditionally, it was accepted that long-term hormone replacement therapy (HRT) has a cardiovascular beneficial effect in postmenopausal women with and without coronary artery disease (CAD). However, randomized trials in postmenopausal women have not shown any benefit in either primary or secondary prevention of cardiovascular events. Therefore, these findings have raised the question of whether traditional HRT (i.e., estrogen and progesterone) has a cardioprotective effect in women at risk for or with established CAD. Concerns about the use of conventional HRT have led to a search for alternatives. Tibolone is a synthetic compound with estrogenic, androgenic, and progestogenic properties that relieves climacteric symptoms and prevents postmenopausal bone loss. Tibolone possesses a tissue-selective mechanism of action that differs from that of estrogen and/or progestogen. Unlike these compounds, tibolone's metabolites play a central role in its mode of action. Tibolone is widely used for HRT. However, its clinical impact on cardiovascular disease is still under study. The current review focuses on the effects of tibolone on the cardiovascular system and discusses clinical investigations with this compound in postmenopausal women. © 2007 The Authors. |
| title |
Cardiovascular effects of tibolone: A selective tissue estrogenic activity regulator |
| title_short |
Cardiovascular effects of tibolone: A selective tissue estrogenic activity regulator |
| title_full |
Cardiovascular effects of tibolone: A selective tissue estrogenic activity regulator |
| title_fullStr |
Cardiovascular effects of tibolone: A selective tissue estrogenic activity regulator |
| title_full_unstemmed |
Cardiovascular effects of tibolone: A selective tissue estrogenic activity regulator |
| title_sort |
cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator |
| publishDate |
2007 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_08975957_v25_n2_p132_Campisi http://hdl.handle.net/20.500.12110/paper_08975957_v25_n2_p132_Campisi |
| _version_ |
1768544091156512768 |